Vertex Reports First Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Crude Inventory Rose 2 Million Barrels Last Week - EIA
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
Vertex Pharma (VRTX) Tops Q1 EPS by 14c, Misses on Revenue; Offers FY26 Revenue Guidance
May 4, 2026 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.47, $0.14 better than the analyst estimate of $4.33. Revenue for the quarter came in at $2.99 billion versus the consensus estimate of $3.03 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $12.95-13.1 billion, versus the consensus of... More
